论文信息 - Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years. - 字舞流文

Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years.

M. Baccarani | G. Martinelli | G. Saglio | S. Soverini | F. Pane | M. Breccia | G. Rosti | F. Castagnetti | F. Palandri | A. Poerio